{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:54Z","timestamp":1789471974060,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-023-02846-4","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T07:01:46Z","timestamp":1691564506000},"page":"4461-4472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Beh\u00e7et syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7889-4532","authenticated-orcid":false,"given":"Cem","family":"Evereklioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-1373","authenticated-orcid":false,"given":"Hatice Kubra","family":"Sonmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1413-2528","authenticated-orcid":false,"given":"Duygu Gulmez","family":"Sevim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-2490","authenticated-orcid":false,"given":"Hatice","family":"Arda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-0170","authenticated-orcid":false,"given":"Hidayet","family":"Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3905-4941","authenticated-orcid":false,"given":"Osman Ahmet","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-6032","authenticated-orcid":false,"given":"Fatih","family":"Horozoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"2846_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C (2005) Current concepts in the etiology and treatment of Beh\u00e7et disease. Surv Ophthalmol 50:297\u2013350","journal-title":"Surv Ophthalmol"},{"key":"2846_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1517\/14656566.5.2.317","volume":"5","author":"C Evereklioglu","year":"2004","unstructured":"Evereklioglu C (2004) Managing the symptoms of Beh\u00e7et\u2019s disease. Expert Opin Pharmacother 5:317\u2013328","journal-title":"Expert Opin Pharmacother"},{"key":"2846_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09629350220131935","volume":"11","author":"C Evereklioglu","year":"2002","unstructured":"Evereklioglu C, Er H, T\u00fcrk\u00f6z Y, \u00c7ekmen M (2002) Serum levels of TNF-\u03b1, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et\u2019s disease. Mediat Inflamm 11:87\u201393","journal-title":"Mediat Inflamm"},{"key":"2846_CR4","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1136\/bjo.2007.127522","volume":"92","author":"C Evereklioglu","year":"2008","unstructured":"Evereklioglu C, Borlu M (2008) Sustained remission after infliximab in a child with systemic vasculitis refractory to conventional immunosuppressive therapy including interferon-\u03b1. Br J Ophthalmol 92:1034","journal-title":"Br J Ophthalmol"},{"key":"2846_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/ICU.0b013e32834bbe91","volume":"22","author":"C Evereklioglu","year":"2011","unstructured":"Evereklioglu C (2011) Ocular Beh\u00e7et disease: current therapeutic approaches. Curr Opin Ophthalmol 22:508\u2013516","journal-title":"Curr Opin Ophthalmol"},{"key":"2846_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop. Am J Ophthalmol 140:509\u2013516","journal-title":"Am J Ophthalmol"},{"key":"2846_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","volume":"924","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 924:467\u2013471","journal-title":"Ophthalmology"},{"key":"2846_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000528593","volume":"14","author":"C Evereklioglu","year":"2023","unstructured":"Evereklioglu C (2023) Twenty years of quiescence after nonstop Remicade\u00ae (Infliximab) infusions in a child with ocular Beh\u00e7et disease presenting as hypopyon-anterior uveitis refractory to immunosuppressants. Case Rep Ophthalmol 14:75\u201382","journal-title":"Case Rep Ophthalmol"},{"key":"2846_CR9","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/art.41026","volume":"71","author":"B Atienza-Mateo","year":"2019","unstructured":"Atienza-Mateo B, Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Demetrio-Pablo R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J et al (2019) Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease: national multicenter study of 177 cases. Arthritis Rheumatol 71:2081\u20132089","journal-title":"Arthritis Rheumatol"},{"key":"2846_CR10","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","unstructured":"D\u00edaz-Llopis M, Salom D, Garcia-de-Vicu\u00f1a C, Cordero-Coma M, Ortega G, Ortego N et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575\u20131581","journal-title":"Ophthalmology"},{"key":"2846_CR11","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","volume":"53","author":"V Calvo-R\u00edo","year":"2014","unstructured":"Calvo-R\u00edo V, Blanco R, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Mesquida M, Ad\u00e1n A et al (2014) Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 53:2223\u20132231","journal-title":"Rheumatology (Oxford)"},{"key":"2846_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, Quan Dong Nguyen QD, Thorne JE, Kestelyn P et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375:932\u2013943","journal-title":"N Engl J Med"},{"key":"2846_CR13","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1136\/bjophthalmol-2017-311234","volume":"102","author":"JT Lee","year":"2018","unstructured":"Lee JT, Yates WB, Rogers S, Wakefield D, McCluskey P, Lim LL (2018) Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol 102:1672\u20131678","journal-title":"Br J Ophthalmol"},{"key":"2846_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","volume":"77","author":"P Quartier","year":"2018","unstructured":"Quartier P, Baptiste A, Despert V, Allain-Launay E, Kon\u00e9-Paut I, Belot A (2018) ADJUVITE Study Group. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis 77:1003\u20131011","journal-title":"Ann Rheum Dis"},{"key":"2846_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S (2017) Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183\u2013189","journal-title":"Clin Rheumatol"},{"key":"2846_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","volume":"125","author":"JL Mart\u00edn-Varillas","year":"2018","unstructured":"Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Beltr\u00e1n E, S\u00e1nchez-Burs\u00f3n J, Mesquida M, Ad\u00e1n A (2018) Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease. Ophthalmology 125:1444\u20131451","journal-title":"Ophthalmology"},{"key":"2846_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12348-019-0181-z","volume":"9","author":"M Ho","year":"2019","unstructured":"Ho M, Chen LJ, Sin HPY, Lu LPL, Brelen M, Ho ACH (2019) Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet\u2019s disease-related uveitis. J Ophthalmic Inflamm Infect 9:14","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2846_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10787-020-00697-4","volume":"28","author":"E Silvestri","year":"2020","unstructured":"Silvestri E, Bitossi A, Bettiol A, Emmi G, Urban ML, Mattioli I (2020) Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Beh\u00e7et\u2019s syndrome. Inflammopharmacology 28:711\u2013718","journal-title":"Inflammopharmacology"},{"key":"2846_CR19","doi-asserted-by":"publisher","first-page":"107430","DOI":"10.1016\/j.intimp.2021.107430","volume":"93","author":"S Yang","year":"2021","unstructured":"Yang S, Huang Z, Liu X, Li H, Xie L, Chen X (2021) Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Beh\u00e7et\u2019s uveitis with vasculitis. Int Immunopharmacol 93:107430","journal-title":"Int Immunopharmacol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02846-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02846-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02846-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T15:04:00Z","timestamp":1702652640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02846-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2846"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02846-4","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"25 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants, and written informed consent was obtained from the parents of pediatric cases in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This submission has not been published anywhere previously and it is not simultaneously being considered for any other publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was reviewed and approved by the department\u2019s academic board and the ethics committee of Erciyes University, Kayseri, T\u00fcrkiye (No: 2020\/76).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}